Formycon AG (FSB: FYB, Prime Standard) announced it will publish its financial results for the fiscal year 2025 on April 22, 2026. The Management Board will discuss the company's development, key financial figures, and provide an outlook for the 2026 fiscal year during a conference call broadcast live on the internet. The call, conducted in English, is scheduled for Wednesday, April 22, 2026, at 3:00 PM (CEST). Participants can register at https://webcast.meetyoo.de/reg/lNibT8TVWubG. After registration, a confirmation email with individual dial-in data will be sent. The presentation and audio broadcast can be accessed via the webcast link at https://www.webcast-eqs.com/formycon-2025-fy.
Following a brief presentation, the Management Board will be available for analysts' questions. The conference call will be recorded and subsequently accessible on the Formycon website at https://www.formycon.com/en/investor-relations/publications/.
In addition to the financial results announcement, Formycon outlined its participation in several international investor conferences during the second quarter of 2026. Representatives of the Management Board will attend the following events: the Equity Forum Spring Conference in Frankfurt, Germany, on May 11–12, 2026, with CFO Enno Spillner; the publication of Q1 2026 results on May 28, 2026, with CEO Dr. Stefan Glombitza, CFO Enno Spillner, CBO Nicola Mikulcik, and CSO Dr. Andreas Seidl, followed by a conference call and webcast; the Jefferies Global Healthcare Conference in New York City, U.S., on June 2–4, 2026, with CFO Enno Spillner; the mwb research Roundtable on June 8, 2026, with the full Management Board via webcast; the Annual General Meeting on June 10, 2026, in Munich, Germany; and the UBS Life Sciences Conference in London, UK, on June 18, 2026, with CFO Enno Spillner. The full financial calendar is available at https://www.formycon.com/en/investors/financial-calendar/.
Formycon AG is a leading independent developer of high-quality biosimilars, focusing on therapies in ophthalmology, immunology, immuno-oncology, and other key disease areas. The company covers almost the entire value chain from technical development through clinical trials to regulatory approval. For commercialization, Formycon relies on strong partnerships worldwide. With FYB201/ranibizumab and FYB202/ustekinumab, Formycon already has two biosimilars on the market. Another biosimilar, FYB203/aflibercept, has been approved by the FDA, EMA, and MHRA. Four pipeline candidates—including FYB208/dupilumab—are currently in development. By providing affordable biosimilars, Formycon contributes to expanding patient access to effective biopharmaceutical medicines.
The biosimilar market is growing rapidly. Global sales of biosimilars currently amount to around $21 billion, and analysts project sales could rise to over $74 billion by 2030. This growth is driven by the patent expiration of many biopharmaceutical drugs, including 45 blockbusters with an estimated total annual global turnover of more than $200 billion by 2032. Biosimilars create competition, reduce healthcare costs, and increase patient access to biopharmaceutical therapies in highly regulated markets such as the EU, USA, Canada, Japan, and Australia.
Formycon AG is headquartered in Munich and listed in the Prime Standard of the Frankfurt Stock Exchange: FYB / ISIN: DE000A1EWVY8 / WKN: A1EWVY. Further information can be found at https://www.formycon.com/.
